HOME >> MEDICINE >> NEWS
Data showed improved quality of life and patient satisfaction with SYMBICORT

Wilmington, DE May 22, 2007 New data demonstrated that the combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dihydrate), led to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol) or placebo. The results from these two 12-week randomized, double-blind trials were presented at the American Thoracic Society (ATS) 2007 International Conference held in San Francisco, May 18-23.

"Asthma is a chronic disease that can have a significant effect on patients' day-to-day routine, including participating in activities, such as walking to the store or even playing with their children," said Dr. Kevin R. Murphy, Clinical Professor, University of Nebraska Medical Center. "For the millions of asthma sufferers in the U.S., and especially for those whose condition is not adequately controlled with their current medication, SYMBICORT will provide a new option for patients to help manage and control their asthma, allowing them to get back to their daily activities."

SYMBICORT is a recently approved, combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older. SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma. Studies of patients treated with SYMBICORT demonstrated clinically significant improvement in lung function occurring within 15 minutes of beginning treatment. SYMBICORT has safety data in long-term studies of up to one year, and has a robust cardiac safety profile.

"The studies presented at this year's ATS conference provided valuable data on asthma control and asthma-related quality of life with SYMBICORT," said Chris O'Brien, Senior Director, Medical Science, AstraZeneca. "Asthma sufferers will have a new, rapid-acting combination treatment to help them achieve asthma control."

Administere
'"/>

Contact: Tracy Knudsen
Tracy.Knudsen@astrazeneca.com
302-885-1933
AstraZeneca
22-May-2007


Page: 1 2 3

Related medicine news :

1. New analysis showed UC patients in clinical remission had higher rates of employment
2. ROZEREM (ramelteon) showed significant reduction in time to fall asleep
3. New study showed ramelteon helped adults with chronic insomnia fall asleep, sleep longer
4. LSUHSC awarded designation resulting in improved patient safety and outcomes
5. ACP supports improved access to information on relative strengths and weaknesses
6. Performance-related financial incentives for hospitals not linked with improved quality of care
7. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms
8. Alzheimers weight gain initiative also improved patients intellectual abilities
9. Acute coronary syndrome therapy improvements linked with fewer deaths and improved clinical outcomes
10. New study reports improved treatment and reduced mortality for patients with heart failure
11. Lymph node evaluation linked to improved survival for colon cancer patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... , ... March 28, 2017 , ... With less than ... acne, access to quality care can be limited while the desire to conquer breakouts ... customized prescription acne care for every customer online, today released its inaugural survey on ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & ... money to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and ... of $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a ...
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the Board ... of Integrative Medicine and available for application on Saturday, May 27, 2017, following ... in Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of the ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice Treatment Center® ... March 13-16, was a busy spot this year. Liz Solovay and Adrian Picheny, ... preventing outbreaks among camp communities during the upcoming 2017 camping season. “Lice infestations ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence ... Dermatology has a lot to offer to the discussion of dealing with excess skin ... that there are many home remedies that can help remove the oily shine while keeping ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... CITY, Calif. , March 28, 2017 /PRNewswire/ ... company focused on the development and commercialization of ... pain, announced that the European Medicines Agency (EMA) ... sublingual tablet, 30 mcg) Marketing Authorisation Application (MAA) ... of the MAA is underway. The MAA for ...
(Date:3/28/2017)... March 28, 2017  Medeon Biodesign, Inc., a ... is pleased to announce that the Company led ... Panther Orthopedics, Inc., a San Jose, ... solutions for orthopedic extremity applications.  ... rapidly, primarily due to procedure volume growth, lifestyle ...
(Date:3/27/2017)... Israel , March 27, 2017 ... THXBY), a specialty clinical-stage pharmaceutical company specializing in the development ... its public offering in the United ... (ADSs), each ADS representing 40 ordinary shares of ... ADS. In addition, Therapix has granted the underwriters ...
Breaking Medicine Technology:
Cached News: